| Product Sales year-on-year analysis: H1 2026 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | World | | US | | Emerging Markets | | Europe | | Established RoW | For the half year ended 30 June | | | | Change | | | | Change | | | | Change | | | | Change | | | | Change | | | $m | | Act % | | CER % | | $m | | Act % | | $m | | Act % | | CER % | | $m | | Act % | | CER % | | $m | | Act % | | CER % | Tagrisso | | 3,775 | | 8 | | 6 | | 1,579 | | 10 | | 1,048 | | 4 | | - | | 769 | | 17 | | 8 | | 379 | | (1) | | 2 | Imfinzi | | 3,548 | | 31 | | 29 | | 2,008 | | 28 | | 398 | | 35 | | 32 | | 781 | | 45 | | 34 | | 361 | | 15 | | 20 | Calquence | | 1,944 | | 19 | | 16 | | 1,286 | | 18 | | 137 | | 33 | | 26 | | 442 | | 20 | | 11 | | 79 | | 9 | | 7 | Lynparza | | 1,610 | | 3 | | (1) | | 659 | | (4) | | 343 | | 6 | | (1) | | 480 | | 13 | | 4 | | 128 | | 1 | | 3 | Enhertu | | 662 | | 55 | | 49 | | - | | - | | 440 | | 51 | | 47 | | 132 | | 41 | | 28 | | 90 | | n/m | | n/m | Zoladex | | 607 | | 7 | | 2 | | 9 | | 4 | | 480 | | 9 | | 4 | | 81 | | 13 | | 5 | | 37 | | (16) | | (18) | Truqap | | 431 | | 43 | | 41 | | 306 | | 21 | | 35 | | n/m | | n/m | | 65 | | n/m | | n/m | | 25 | | 98 | | n/m | Imjudo | | 160 | | (6) | | (7) | | 100 | | 10 | | 13 | | 9 | | 8 | | 28 | | 22 | | 13 | | 19 | | (22) | | (19) | Datroway | | 5 | | n/m | | n/m | | - | | - | | 5 | | n/m | | n/m | | - | | - | | - | | - | | - | | - | Etcamah | | 3 | | n/m | | n/m | | - | | - | | 3 | | n/m | | n/m | | - | | - | | - | | - | | - | | - | Other Oncology | | 203 | | (6) | | (8) | | 4 | | (1) | | 141 | | (3) | | (6) | | 8 | | (19) | | (30) | | 50 | | (12) | | (7) | Oncology | | 12,948 | | 17 | | 14 | | 5,951 | | 15 | | 3,043 | | 16 | | 11 | | 2,786 | | 26 | | 16 | | 1,168 | | 9 | | 11 | Farxiga | | 3,997 | | (5) | | (11) | | 668 | | (17) | | 1,618 | | (6) | | (13) | | 1,586 | | 10 | | 1 | | 125 | | (45) | | (45) | Crestor | | 685 | | 8 | | 4 | | 18 | | (23) | | 612 | | 12 | | 8 | | 1 | | n/m | | 80 | | 54 | | (16) | | (13) | Brilinta | | 186 | | (64) | | (66) | | 16 | | (94) | | 142 | | 4 | | - | | 24 | | (78) | | (80) | | 4 | | (35) | | (33) | Lokelma | | 419 | | 28 | | 26 | | 164 | | 14 | | 93 | | 47 | | 41 | | 87 | | 56 | | 44 | | 75 | | 17 | | 23 | Seloken | | 337 | | 9 | | 5 | | - | | - | | 326 | | 9 | | 5 | | 9 | | 5 | | 5 | | 2 | | (1) | | (8) | roxadustat | | 57 | | (62) | | (64) | | - | | - | | 57 | | (62) | | (64) | | - | | - | | - | | - | | - | | - | Wainua | | 121 | | 44 | | 44 | | 109 | | 33 | | 4 | | n/m | | n/m | | 7 | | n/m | | n/m | | 1 | | n/m | | n/m | Baxfendy | | 3 | | n/m | | n/m | | 2 | | n/m | | 1 | | n/m | | n/m | | - | | - | | - | | - | | - | | - | Other CVRM | | 206 | | (25) | | (28) | | (9) | | n/m | | 145 | | 5 | | 1 | | 42 | | (45) | | (49) | | 28 | | (14) | | (11) | CVRM | | 6,011 | | (8) | | (12) | | 968 | | (28) | | 2,998 | | (2) | | (7) | | 1,756 | | 3 | | (5) | | 289 | | (27) | | (25) | Symbicort | | 1,418 | | (1) | | (4) | | 545 | | (9) | | 417 | | 4 | | - | | 296 | | 9 | | 1 | | 160 | | (5) | | (8) | Fasenra | | 1,053 | | 14 | | 12 | | 594 | | 7 | | 92 | | 75 | | 69 | | 258 | | 13 | | 4 | | 109 | | 31 | | 33 | Breztri | | 699 | | 20 | | 17 | | 309 | | 5 | | 208 | | 34 | | 27 | | 127 | | 45 | | 34 | | 55 | | 24 | | 24 | Tezspire | | 321 | | 62 | | 54 | | - | | - | | 44 | | n/m | | n/m | | 202 | | 57 | | 46 | | 75 | | 39 | | 43 | Saphnelo | | 380 | | 25 | | 24 | | 318 | | 20 | | 11 | | 67 | | 63 | | 36 | | 71 | | 57 | | 15 | | 40 | | 44 | Pulmicort | | 269 | | 2 | | (3) | | 3 | | (6) | | 219 | | 5 | | - | | 31 | | (9) | | (16) | | 16 | | (16) | | (17) | Airsupra | | 87 | | 24 | | 23 | | 78 | | 12 | | 9 | | n/m | | n/m | | - | | - | | - | | - | | - | | - | Other R&I | | 130 | | (18) | | (21) | | 15 | | (73) | | 55 | | (22) | | (26) | | 57 | | 97 | | 88 | | 3 | | (1) | | (4) | R&I | | 4,357 | | 11 | | 8 | | 1,862 | | 1 | | 1,055 | | 16 | | 11 | | 1,007 | | 26 | | 17 | | 433 | | 13 | | 13 | Beyfortus | | 71 | | (44) | | (44) | | 61 | | (40) | | - | | - | | - | | 9 | | (62) | | (63) | | 1 | | (38) | | (29) | FluMist | | 26 | | n/m | | n/m | | (2) | | n/m | | 1 | | n/m | | n/m | | - | | - | | - | | 27 | | n/m | | n/m | Other ID | | 92 | | (43) | | (47) | | (1) | | (40) | | 70 | | (42) | | (46) | | 16 | | (39) | | (46) | | 7 | | (60) | | (58) | ID* | | 189 | | (37) | | (40) | | 58 | | (42) | | 71 | | (41) | | (45) | | 25 | | (51) | | (55) | | 35 | | 21 | | 18 | Ultomiris | | 2,584 | | 16 | | 14 | | 1,398 | | 10 | | 190 | | 68 | | 65 | | 605 | | 22 | | 12 | | 391 | | 13 | | 17 | Soliris | | 778 | | (20) | | (22) | | 414 | | (27) | | 248 | | 10 | | 6 | | 61 | | (46) | | (50) | | 55 | | (20) | | (21) | Strensiq | | 1,053 | | 41 | | 40 | | 859 | | 47 | | 65 | | 30 | | 13 | | 68 | | 20 | | 10 | | 61 | | 10 | | 14 | Koselugo | | 347 | | 26 | | 21 | | 94 | | (11) | | 115 | | 52 | | 42 | | 99 | | 39 | | 28 | | 39 | | 74 | | 80 | Other Rare Disease | | 149 | | 32 | | 25 | | 58 | | 7 | | 34 | | 73 | | 47 | | 41 | | 20 | | 10 | | 16 | | n/m | | n/m | Rare Disease | | 4,911 | | 13 | | 11 | | 2,823 | | 9 | | 652 | | 35 | | 28 | | 874 | | 13 | | 4 | | 562 | | 13 | | 16 | Other Medicines | | 480 | | (6) | | (8) | | 42 | | 6 | | 359 | | (9) | | (11) | | 39 | | 12 | | 8 | | 40 | | (3) | | (3) | Total Medicines | | 28,896 | | 8 | | 5 | | 11,704 | | 6 | | 8,178 | | 8 | | 3 | | 6,487 | | 16 | | 7 | | 2,527 | | 4 | | 6 |
The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. * ID: Infectious Disease
|